P
Philip C. Calder
Researcher at University of Southampton
Publications - 808
Citations - 70822
Philip C. Calder is an academic researcher from University of Southampton. The author has contributed to research in topics: Polyunsaturated fatty acid & Eicosapentaenoic acid. The author has an hindex of 125, co-authored 747 publications receiving 59110 citations. Previous affiliations of Philip C. Calder include Southampton General Hospital & Radboud University Nijmegen Medical Centre.
Papers
More filters
Journal ArticleDOI
Plasma amino acid concentrations in the overtraining syndrome: possible effects on the immune system.
M. Parry-Billings,Richard Budgett,Yiannis Koutedakis,Eva Blomstrand,Steven Brooks,Clyde Williams,Philip C. Calder,Sian Pilling,Robert Baigrie,Eric A. Newsholme +9 more
TL;DR: It is concluded that the decrease in plasma glutamine concentration in overtraining and following long-term exercise, and not an intrinsic defect in T lymphocyte function, may contribute to the immune deficiency reported in these conditions.
Journal ArticleDOI
Polyunsaturated fatty acids and inflammation.
TL;DR: The anti-inflammatory actions of long chain n-3 fatty acid-induced effects may be of therapeutic use in conditions with an acute or chronic inflammatory component.
Journal ArticleDOI
Dietary α-linolenic acid and health-related outcomes: a metabolic perspective
TL;DR: Overall, the limited capacity for conversion to longer-chain n-3 fatty acids, and the lack of efficacy in ameliorating CVD risk factors and inflammatory markers in man suggests that increased consumption of αLNA may be of little benefit in altering EPA+DHA status or in improving health outcomes compared with other dietary interventions.
Journal ArticleDOI
Differential effects of short-chain fatty acids on proliferation and production of pro- and anti-inflammatory cytokines by cultured lymphocytes.
Cláudia Regina Cavaglieri,Anita Nishiyama,L C Fernandes,Rui Curi,Elizabeth A. Miles,Philip C. Calder +5 more
TL;DR: It is concluded that butyrate significantly inhibits Th1-type responses and that this might explain the therapeutic effect ofbutyrate in IBD patients.
Journal ArticleDOI
Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease.
TL;DR: These studies fail to reveal strong dose–response effects of EPA+DHA on the outcomes measured and suggest that healthy subjects are relatively insensitive to immunomodulation with long-chain n-3 PUFA, even at intake levels that substantially raise their concentrations in phospholipids of immune cells.